Comparative efficacy and safety of oral P2Y 12 inhibitors after non-ST-elevation acute coronary syndromes: A network meta-analysis

Comparative efficacy and safety of oral P2Y 12 inhibitors after non-ST-elevation acute coronary syndromes: A network meta-analysis

Background Currently, potent P2Y 12 inhibition with the use of prasugrel or ticagrelor is the mainstay of treatment after an acute coronary syndrome (ACS). The 2020 European Society of Cardiology (ESC) Guidelines recommend the use of prasugrel over ticagrelor in patients with non-ST-elevation ACS (N...

Full description

Bibliographic Details
Main Authors: Doundoulakis, I. (Author), Farmakis, I.T (Author), Giannakoulas, G. (Author), Karagiannidis, E. (Author), Karvounis, H. (Author), Kassimis, G. (Author), Michalis, L.K (Author), Moysidis, D.V (Author), Pagiantza, A. (Author), Stalikas, N. (Author), Zafeiropoulos, S. (Author)
Format: Article
Language:English
Published: BMJ Publishing Group 2022
Subjects:
acute coronary syndrome
coronary artery disease
meta-analysis
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items